Also don't forget the background of the historic AML trials. An average Complete Response of 51% in Phase II trials that reported results between 1987 and 1994 [1]. It's a background that IMO potentially supports further confidence of a strong result in the Israel aka Sheba 2.0 trial.
[1] https://raceoncology.com/wp-content...e-a-review-of-the-literature-ijcrt-17-015.pdf
It was this historic consistency in performance that caused Dr T to stop and take a very careful look at Bisantrene when he reviewed ASX biotech tickers in alphabetical sequence in early 2019.
General Comments / Chat, page-7575
-
- There are more pages in this discussion • 3,531 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.77 |
Change
0.015(0.86%) |
Mkt cap ! $300.6M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.77 | $91.78K | 51.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 31147 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.80 | 8318 | 1 |
View Market Depth
| Last trade - 15.59pm 10/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |